NASDAQ:CERE • US15678U1280
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CEREVEL THERAPEUTICS HOLDING (CERE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-02-16 | Mizuho | Maintains | Neutral -> Neutral |
| 2023-12-28 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023-12-22 | Jefferies | Downgrade | Buy -> Hold |
| 2023-12-08 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-12-07 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-12-07 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-11-20 | JP Morgan | Reiterate | Neutral |
| 2023-11-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-09-28 | Piper Sandler | Initiate | Overweight |
| 2023-08-07 | Mizuho | Maintains | Neutral -> Neutral |
| 2023-08-03 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-08-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-23 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-05-08 | Mizuho | Maintains | Neutral |
| 2023-05-04 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2023-04-10 | TD Cowen | Initiate | Outperform |
| 2023-04-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-17 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-03-16 | Berenberg | Reiterate | Hold |
| 2023-03-09 | Mizuho | Maintains | Neutral |
| 2023-02-23 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-02-23 | Morgan Stanley | Maintains | Overweight |
| 2023-02-23 | HC Wainwright & Co. | Maintains | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 593.29% | N/A 162.99% | N/A 80.54% | N/A 71.26% | N/A 39.33% | ||||||
| EBITDA YoY % growth | N/A | -148.72M | -217.4M -46.18% | -362.95M -66.95% | -441.638M -21.68% | N/A -6.45% | N/A -9.79% | N/A -7.55% | N/A 30.69% | N/A 107.10% | N/A 1,081.34% | N/A 70.72% | N/A | |
| EBIT YoY % growth | -149.12M | -220.1M -47.60% | -367.85M -67.13% | -447.265M -21.59% | N/A -15.30% | N/A -6.79% | N/A -19.18% | N/A 44.04% | N/A 101.38% | N/A 9,190.53% | N/A 183.88% | N/A 53.40% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -1.65 68.75% | -2.33 -41.21% | -2.67 -14.59% | N/A 3.92% | N/A -11.33% | N/A -6.43% | N/A 28.02% | N/A 78.21% | N/A 483.96% | N/A 207.34% | N/A 54.08% |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.72 -14.95% | -0.59 3.85% | -0.67 11.42% | -0.73 -0.60% | -0.74 -2.82% | -0.78 -32.17% | -0.80 -18.18% |
| Revenue Q2Q % growth | |||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -147.9M -52.73% | -137.598M -23.62% | -138.414M 0.82% | -127.5M 10.62% | -130.56M 11.72% | -136.68M 0.67% | -139.74M -0.96% |
All data in USD
14 analysts have analysed CERE and the average price target is 44.27 USD. This implies a price decrease of -1.54% is expected in the next year compared to the current price of 44.96.
CEREVEL THERAPEUTICS HOLDING (CERE) will report earnings on 2024-10-30, before the market open.
The consensus EPS estimate for the next earnings of CEREVEL THERAPEUTICS HOLDING (CERE) is -0.72 USD and the consensus revenue estimate is 0 USD.
The consensus rating for CEREVEL THERAPEUTICS HOLDING (CERE) is 52.8571 / 100 . This indicates that analysts generally have a neutral outlook on the stock.